Drug intelligence / Profile preview

ADB116 (Aidea Pharma)

Development stage: Unknown
Lead developer: AIDEA PHARMA
Modality: Small Molecules
Administration: Intravenous

Overview

ADB116 is an investigational small molecule intravenous anesthetic being developed by Jiangsu Aidea Pharmaceutical Group. It is designed as a Class 1 innovative drug in China, targeting the Gamma-aminobutyric acid type A (GABA_A) receptor as a positive allosteric modulator. The drug is intended for use in the induction and maintenance of general anesthesia and for procedural sedation, aiming to provide a rapid onset and offset of action with a favorable safety profile. ADB116 is currently undergoing Phase I clinical evaluation in healthy volunteers to establish its safety, tolerability, and pharmacokinetic characteristics.

Other names: ADB116 for InjectionADB-116 for InjectionADB 116 for Injection

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on ADB116 (Aidea Pharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADB116 (Aidea Pharma).

Explore the full profile